Search

Your search keyword '"Giulia Cesaretti"' showing total 2 results
Start Over Author "Giulia Cesaretti" Publication Year Range Last 50 years
2 results on '"Giulia Cesaretti"'

1. Ceftazidime–Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study

Author

Maria Di Pietrantonio, Lucia Brescini, Jennifer Candi, Morroni Gianluca, Francesco Pallotta, Sara Mazzanti, Paolo Mantini, Bianca Candelaresi, Silvia Olivieri, Francesco Ginevri, Giulia Cesaretti, Sefora Castelletti, Emanuele Cocci, Rosaria G. Polo, Elisabetta Cerutti, Oriana Simonetti, Oscar Cirioni, Marcello Tavio, Andrea Giacometti, and Francesco Barchiesi

Subjects
Gram-negative pathogens, multidrug resistance, ceftazidime–avibactam, Therapeutics. Pharmacology, RM1-950
Abstract

Background: Ceftazidime/avibactam is a new cephalosporin/beta-lactamase inhibitor combination approved in 2015 by the FDA for the treatment of complicated intra-abdominal and urinary tract infection, hospital-acquired pneumoniae and Gram-negative infections with limited treatment options. Methods: In this retrospective study, we evaluate the efficacy of ceftazidime/avibactam treatment in 81 patients with Gram-negative infection treated in our center from January 2018 to December 2019. The outcome evaluated was 30-days survival or relapse of infection after the first positive blood culture. Results: the majority of patients were 56 male (69%), with median age of 67. Charlson’s Comorbidity Index was >3 in 58 patients. In total, 46% of the patients were admitted into the medical unit, 41% in the ICU, and 14% in the surgical ward. Of the patients, 78% had nosocomial infections, and 22% had healthcare-related infections. The clinical failure rate was 35%: 13 patients died within 30 days from the onset of infection. The outcome was influenced by the clinical condition of the patients: solid organ transplantation (p = 0.003) emerged as an independent predictor of mortality; non-survival patients most frequently had pneumonia (p = 0.009) or mechanical ventilation (p = 0.049). Conclusion: Ceftazidime–avibactam showed high efficacy in infections caused by MDR Gram-negative pathogens with limited therapeutic options.

Published
2022
Full Text
View/download PDF

2. Development of the optimal touchscreen interface for patients with scleroderma

Author

Emanuele Filippini, Rosaria Gesuita, Valentina Maurizi, Agnese Brunzini, Gianluca Moroncini, Alessandra Papetti, Armando Gabrielli, Giulia Cesaretti, and Michele Germani

Subjects
medicine.medical_specialty, Interface (computing), Immunology, education, Original Manuscript, Scleroderma, law.invention, 03 medical and health sciences, 0302 clinical medicine, Physical medicine and rehabilitation, Touchscreen, Quality of life (healthcare), Rheumatology, law, medicine, Immunology and Allergy, 0501 psychology and cognitive sciences, skin and connective tissue diseases, 050107 human factors, 030203 arthritis & rheumatology, Hand function, integumentary system, business.industry, 05 social sciences, medicine.disease, business
Abstract

Impaired hand function is a major contributor to overall disability and reduced health-related quality of life in scleroderma patients. A relevant issue concerns interaction of scleroderma subjects with touchscreen interfaces. This study aims at investigating this problem assessing scleroderma patients’ performance with a novel, aptly designed, touchscreen application in order to identify critical items of touchscreen technology which may impair or facilitate the use by scleroderma subjects. Eighty scleroderma patients performed this novel application including three games, each of which tested a different gesture: tapping, dragging/dropping, and pinching-to-zoom. Eighty healthy subjects without hand impairments were recruited as controls. Scleroderma patients performed worse than healthy users in each game, and statistically significant negatively impacting items were identified. In the second phase of the study, the 10 worst touchscreen performers within the scleroderma cohort were recruited for a physio-rehabilitation trial based on the daily use at home of a modified version of the software application downloaded into the personal devices of patients. The results of this study allow introduction of guidelines to design accessible touchscreen interfaces for subjects with scleroderma and suggest that touchscreen technology may be included in self-administered physio-rehabilitation programs for scleroderma hand.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results